Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- Merck & Co. (MRK) and Novartis AG (NVS) are both major pharmaceutical companies with significant exposure to oncology and innovative drug pipelines.
- Recent market activity shows NVS delivering a Q2 2026 earnings beat that supported share price stability, while MRK prepares for its Q2 results amid multiple regulatory approvals.
- Both stocks have demonstrated resilience in the healthcare sector, with NVS posting stronger year-to-date and one-year returns compared to broader market benchmarks in recent periods.
- MRK benefits from ongoing pipeline catalysts including oncology expansions and new product launches, whereas NVS emphasizes margin stability and reiterated full-year guidance.
- Relative performance highlights trade-offs between MRK’s growth-oriented developments and NVS’s demonstrated earnings consistency in the latest reporting cycle.
- Sector sentiment remains supportive for both amid broader healthcare innovation trends, though each faces typical pharmaceutical risks such as patent expirations and regulatory timelines.
Introduction
Merck & Co. (MRK) and Novartis AG (NVS) represent two leading players in the global pharmaceutical industry, making them relevant for comparison by investors and traders seeking exposure to healthcare innovation and established drug portfolios. This analysis examines their business models, recent performance dynamics, and relative positioning within the sector. Professional and retail investors monitoring large-cap biopharma stocks may find the comparison useful for understanding differences in growth drivers, earnings delivery, and market sentiment. The focus remains on verifiable developments to provide a balanced view of how each company has navigated recent market conditions.
MRK Overview and Recent Performance
Merck & Co. (MRK) operates as a global healthcare company focused on oncology, vaccines, hospital acute care, and animal health. Its flagship product Keytruda continues to drive revenue through expanded indications. In recent weeks, the company secured multiple U.S. and EU regulatory approvals for Keytruda combinations in areas such as muscle-invasive bladder cancer and renal cell carcinoma. Additional developments included an FDA approval for a first-in-class oral cholesterol-lowering drug and licensing agreements for an experimental HIV prevention pill across 129 countries. MRK stock has traded in a range influenced by these pipeline updates and anticipation of its Q2 2026 earnings report scheduled for early August. Analyst price targets have been revised upward, reflecting attention to upcoming catalysts. Broader market activity shows the shares maintaining positions within their 52-week range amid sector rotation in healthcare.
NVS Overview and Recent Performance
Novartis AG (NVS) is a multinational pharmaceutical company with a portfolio spanning oncology, cardiovascular, neuroscience, and immunology. The firm emphasizes innovation-driven growth and operational efficiency. In recent weeks, NVS reported Q2 2026 results that exceeded earnings expectations, with core operating income and sales figures supporting management’s reiterated full-year guidance for low-single-digit sales growth. Shares responded positively following the July earnings release, contributing to year-to-date returns that outpaced certain market indices. Performance metrics indicate continued strength in key therapeutic areas and margin resilience despite pressures from older product declines. Recent market activity reflects investor focus on the company’s ability to sustain innovation-led growth within the pharmaceutical sector.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in this section. Available bots span a wide array of trading styles, strategies, timeframes, and performance statistics, allowing users to evaluate options suited to different risk profiles and objectives. Metrics such as win rates, drawdowns, and trade frequency vary significantly among the bots, providing transparency for comparison. This resource serves as an informational hub for market participants interested in automated trading approaches. Explore the Trending AI Robots page for further details on current selections.
Head-to-Head Comparison
Merck & Co. (MRK) and Novartis AG (NVS) both operate diversified pharmaceutical businesses with heavy emphasis on oncology, yet differ in recent execution and positioning. MRK’s growth profile centers on Keytruda expansions and new product approvals, offering potential catalysts through regulatory milestones, while NVS has highlighted earnings consistency and guidance reaffirmation in its latest quarter. In terms of recent momentum, NVS delivered a clear earnings beat that supported price stability, whereas MRK’s activity has centered on pipeline news ahead of its own reporting. Risk factors for both include typical industry challenges such as competition, reimbursement pressures, and development timelines. Sector exposure remains comparable within healthcare, though MRK carries notable animal health diversification. Market sentiment appears constructive for both, with analysts adjusting targets upward for MRK and NVS demonstrating outperformance relative to benchmarks over trailing periods. Trade-offs include MRK’s higher visibility around upcoming results versus NVS’s more established recent earnings delivery.
Tickeron AI Verdict
Based on observable factors including earnings delivery consistency, regulatory momentum, and relative price behavior in recent market activity, Tickeron’s AI models currently assign a modest probabilistic edge to Novartis AG (NVS). The stock’s Q2 results and guidance stability provide a foundation of demonstrated performance, while Merck & Co. (MRK) awaits its reporting cycle amid pipeline developments. This assessment reflects trend consistency and positioning rather than certainty, as both companies operate in a dynamic sector where outcomes depend on multiple variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 2 bullish TA indicator(s).
- MRK’s TA Score: 4 bullish, 4 bearish.
- NVS’s TA Score: 2 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +5.65% price change this week, while NVS (@Pharmaceuticals: Major) price change was -3.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | NVS | MRK / NVS | |
| Capitalization | 335B | 286B | 117% |
| EBITDA | 19.4B | 22.5B | 86% |
| Gain YTD | 30.943 | 12.744 | 243% |
| P/E Ratio | 108.67 | 22.79 | 477% |
| Revenue | 65.8B | 56.7B | 116% |
| Total Cash | N/A | 7.69B | - |
| Total Debt | 49.1B | 49B | 100% |
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 40 | 7 | |
SMR RATING 1..100 | 47 | 34 | |
PRICE GROWTH RATING 1..100 | 9 | 52 | |
P/E GROWTH RATING 1..100 | 2 | 26 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (61). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (40). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
NVS's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (52). This means that MRK’s stock grew somewhat faster than NVS’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (26). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | N/A |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 49% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 54% | 2 days ago 43% |
| TrendWeek ODDS (%) | 2 days ago 57% | 2 days ago 43% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 57% | 19 days ago 52% |
| Declines ODDS (%) | 17 days ago 51% | 2 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 32% |
| Aroon ODDS (%) | 2 days ago 63% | N/A |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.